Dergiler / Infectious diseases and clinical microbiology (Online) / 2020 / Cilt: 2 - Sayı: 1

Adverse Cardiac Events Related toHydroxychloroquine Prophylaxis andTreatment of COVID-19

Sayfa
24–26
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We present three case reports of cardiovascular adverse effects, with respect to its propensity to cause QT interval prolongation and potentially serious cardiac arrhythmias.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Coronavirus disease 2019 (COVID-19) was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020.
📊
Temel Bulgular & Veri:The disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV).
💡
Sonuç & Katkı:We present three case reports of cardiovascular adverse effects, with respect to its propensity to cause QT interval prolongation and potentially serious cardiac arrhythmias.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Coronavirus disease 2019 (COVID-19) was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. The disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). The measures to contain the spread of the disease such as social-distancing, hand hygiene, contact tracing, and isolation of persons suspected or confirmed to have the infection have been considered to be largely effective. No specific drugs for COVID-19 have been proven to be effective currently for either prophylaxis or treatment. However, hydroxychloroquine (HCQ) was suggested as one of the choices of the drug, despite the lack of evidence-based information. We present three case reports of cardiovascular adverse effects, with respect to its propensity to cause QT interval prolongation and potentially serious cardiac arrhythmias.

🔖

Bu Makaleye Atıf Yap

SARIKAYA, Z. T., ERGÖNÜL, Ö., ÇUHADAROĞLU, Ç., KOCAGÖZ, S., ZENGİN, R., KARADAĞ, N. (2022). Adverse Cardiac Events Related toHydroxychloroquine Prophylaxis andTreatment of COVID-19. Infectious diseases and clinical microbiology (Online), Cilt: 2 - Sayı: 1, 24–26. https://ajindex.com/articles/539116

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. 1 COVID-19 (SARS-CoV-2) Guideline of Scientific Advisory Board of Turkey, Ministry of Health of Turkey, 14 April, 2020, Ankara. 2 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 11 April 2020. Available from: URL: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ 3 Prophylactic use of hydroxychloroquine. Turkish Society of Clinical Microbiology and Infectious Diseases, 21 March 2020. Available from: URL: https://www.klimik.org.tr/2020/03/20/ hidroksiklorokinin-covid-19-hastalarinda-ve-hastaligin-profilaksisinde-kullanimi-konusunda-klimik-dernegi-gorusu/ 4 Aktoz M, Altay H, Aslanger E, Atalar E, Aytekin V, Baykan AO, et al. Türk Kardiyoloji Derneği Uzlaşı Raporu: COVID-19 Pandemisi ve Kardiyovasküler Hastalıklar Konusunda Bilinmesi Gerekenler (25 Mart 2020) [Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)]. Turk Kardiyol Dern Ars 2020
  2. doi:10.5543/tkda.2020.97198. 5 Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020
  3. doi:10.1038/s41421-020-0156-0 6 Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020
  4. 105932. doi: 10.1016/j.ijantimicag.2020.105932. 7 Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care 2013
  5. doi: 10.1177/2048872612471215. 8 Gendrot M, Javelle E, Le Dault E, Clerc A, Savini H, Pradines B. Chloroquine as a prophylactic agent against COVID-19? Int J Antimicrob Agents 2020 Apr 12
  6. 105980. doi:10.1016/j.ijantimicag.2020.105980. [Epub ahead of print]. 9 Magagnoli J, Narendran S, Pereira F, Cummings T, WHardin J, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv 2020.04.16.20065920
  7. doi: https://doi.org/10.1101/2020.04.1 6.20065920